# Inovio Pharmaceuticals

> Inovio Pharmaceuticals is a VC fund backing Health Care and Therapeutics. See 3 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Plymouth Meeting, United States
- Total investments: 3
- Last investment: Mar 2022
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/inovio-pharmaceuticals
- X (Twitter): http://twitter.com/InovioPharma
- Website: http://www.inovio.com
- Facebook: https://www.facebook.com/INOVIOPharmaceuticals

Inovio Pharmaceuticals is a VC fund in Plymouth Meeting focused on Health Care and Therapeutics. INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. INOVIO is the first and only company to have clinically demonstrated that DNA medicine can be delivered directly into cells in the body via aproprietary smart device to produce a robust and tolerable immune response. Specifically, INOVIO's lead candidate VGX-3100, currently in Phase 3 trials for precancerous cervical dysplasia, demonstrated it destroyed and cleared high-risk HPV 16 and 18 in a Phase 2b clinical trial. High-risk HPV is responsible for 70% of cervical cancer, 90% of anal cancer, and 69% of vulvar cancer.

## Contacts

5 contacts available for Inovio Pharmaceuticals. Shizune tracks 7 team members at Inovio Pharmaceuticals. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/inovio-pharmaceuticals?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 1 | 33% |
| Therapeutics | 1 | 33% |
| Biotechnology | 1 | 33% |
| Pharmaceutical | 1 | 33% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Jacqueline Shea | Chief Executive Officer | 0 | — |
| Laurent Humeau | Chief Scientific Officer; Executive Vice President of Research, Engineering and Clinical Developments | 0 | — |
| Michael Sumner | Chief Medical Officer | 0 | — |
| Paul Fisher | Director of Bioengineering | 0 | — |
| Peter Kies | Chief Financial Officer | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Geneos Therapeutics | Geneos is developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment. The company's technology is designed to identify relevant neoantigen targets from individual patient tumors to develop novel treatments for cancer, providing patients with tumor targeted immunotherapies to cure their disease. | $17M | Series A | Mar 24, 2022 |  |
| Geneos Therapeutics | Geneos is developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment. The company's technology is designed to identify relevant neoantigen targets from individual patient tumors to develop novel treatments for cancer, providing patients with tumor targeted immunotherapies to cure their disease. | $12M | Series A | Mar 03, 2021 |  |
| Geneos Therapeutics | Geneos is developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment. The company's technology is designed to identify relevant neoantigen targets from individual patient tumors to develop novel treatments for cancer, providing patients with tumor targeted immunotherapies to cure their disease. | $10.5M | Series A | Feb 21, 2019 |  |

3 of 3 investments shown.

## Co-investors
- [Sante Ventures](https://shizune.co/investors/profile/sante-ventures) — VC Fund, 3 deals together
- [Korea Investment Partners](https://shizune.co/investors/profile/korea-investment-partners) — VC Fund, 2 deals together
- [Flerie Invest](https://shizune.co/investors/profile/flerie-invest) — VC Fund, 1 deal together
- Global Bio Fund — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Inovio Pharmaceuticals invest in?

Inovio Pharmaceuticals invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series A stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Inovio Pharmaceuticals?

Public channels for Inovio Pharmaceuticals include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Inovio Pharmaceuticals?

The team at Inovio Pharmaceuticals includes Jacqueline Shea (Chief Executive Officer), Laurent Humeau (Chief Scientific Officer; Executive Vice President of Research, Engineering and Clinical Developments) and Michael Sumner (Chief Medical Officer), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co